CBRE Group
CBRE
$140.51
+1.83%
CBRE Group is the world's largest commercial real estate services and investment firm, generating revenue through brokerage and leasing, facilities and project management, valuation, mortgage servicing, and investment management across every major property type and more than 100 countries. Its scale, global footprint, and diversified service mix make it the industry's dominant platform rather than a niche specialist, with a workforce of roughly 155,000 employees and a market capitalization near $44-48 billion. The current investor debate centers on whether CBRE can convert a cyclical recovery in transaction volumes into durable earnings growth, given that Q1 2026 revenue rose 18.2% year over year to $10.53 billion but net income of $318 million translated into a thin 3.0% net margin. Sentiment has been pressured by a broader rotation away from real estate and automation-exposed services names, with the stock down 15.3% over the past year even as the S&P 500 gained 16.2%, leaving investors weighing whether the recent stabilization in leasing and capital markets activity marks an inflection point or a false start.…
CBRE
CBRE Group
$140.51
Investment Opinion: Should I buy CBRE Today?
Rating: Buy. The core thesis is that CBRE is the dominant platform in commercial real estate services, trading at a reasonable forward PE of 15.45x with 30.2% upside to the analyst average target of $182.92, as a cyclical recovery in transaction volumes drives operating leverage and earnings growth. The unanimous buy consensus (recommendation mean 1.54) and recent positive actions from UBS, Barclays, Evercore ISI, and KBW reinforce confidence in the recovery trajectory.
Supporting evidence includes: 1) Revenue growth of 18.15% YoY in Q1 2026, accelerating from prior quarters; 2) Net income nearly doubling from $163 million to $318 million YoY, with EBITDA up from $518 million to $695 million; 3) Forward PE of 15.45x versus trailing PE of 41.44x, implying significant earnings normalization; 4) Analyst target upside of 30.2% to $182.92, with a high target of $200.00; and 5) PS ratio of 1.18x and EV/Sales of 1.145x, which are low on an absolute basis for a market leader. While no direct industry average PE is provided, the low sales multiple and high PB ratio (5.40x) suggest the market is pricing in a recovery but not yet rewarding the stock for it.
The biggest risks that could invalidate the thesis are: 1) A stall in commercial real estate transaction volumes, which would keep margins compressed near 3% and prevent the earnings normalization implied by the forward PE; 2) Continued negative free cash flow and working capital outflows, which could strain liquidity given the 1.095 current ratio; and 3) Further multiple compression if the stock's underperformance versus SPY persists, potentially driven by sector rotation away from real estate. The rating would upgrade to a strong buy if revenue growth accelerates above 20% and operating margins expand above 6%, or downgrade to a hold if revenue growth decelerates below 10% or if free cash flow remains negative for multiple quarters. On valuation, CBRE appears fairly valued to slightly undervalued on a forward basis (15.45x forward PE) but overvalued on trailing metrics (41.44x PE, 5.40x PB), suggesting the market is pricing in a successful recovery that has yet to fully materialize.
Sign up to view all
CBRE 12-Month Price Forecast
CBRE presents a compelling recovery story with revenue growth of 18.15% YoY, net income nearly doubling, and a forward PE of 15.45x that is reasonable for a market leader. The unanimous analyst buy consensus and 30.2% upside to the average target of $182.92 suggest the market has not yet priced in the recovery. However, the stock's 31.52 percentage point underperformance versus SPY over the past year and thin 3.02% net margin highlight the risks. The key tension is whether the revenue acceleration is sustainable or merely a cyclical bounce. I would upgrade to high confidence if Q2 2026 shows continued revenue growth above 15% and positive free cash flow, or downgrade to neutral if revenue growth decelerates below 10% or if operating margins fail to expand.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on CBRE Group's 12-month outlook, with a consensus price target around $182.92 and implied upside of +30.2% versus the current price.
Average Target
$182.92
0 analysts
Implied Upside
+30.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$144 - $200
Analyst target range
Coverage of CBRE is solid with 12 analysts, and the consensus is decisively bullish: the recommendation is "buy" with a recommendation mean of 1.54 (where 1.0 is a strong buy and 3.0 is a hold), and the average target price of $182.92 implies 30.2% upside from the current price of $140.51. The target range spans from a low of $144.00 (just 2.5% above the current price) to a high of $200.00 (42.3% upside), a spread of $56 or roughly 31% of the average target, which signals meaningful disagreement about the pace and magnitude of the recovery. The consensus EPS estimate of $13.45, with a range of $13.05 to $14.30, and estimated revenue of $62.83 billion, with a range of $61.40 billion to $65.90 billion, frame the fundamental expectations underpinning these targets. The bullish tilt is reinforced by the institutional ratings flow, which shows a clear pattern of upgrades and reiterations: UBS upgraded to Buy from Neutral on February 23, 2026, while Barclays (Overweight), Evercore ISI (Outperform), and Keefe, Bruyette & Woods (Outperform) have all reiterated positive ratings throughout 2026 with no downgrades in the visible data. The high target of $200.00 likely assumes a full cyclical recovery in transaction volumes, multiple expansion back toward historical mid-cycle levels, and successful operating leverage on the 18% revenue growth trajectory. The low target of $144.00, barely above the current price, prices in a scenario where the recovery stalls, margins remain compressed near the 3% net margin level, and the stock simply holds its ground rather than re-rating. The tight clustering of recent analyst actions around Outperform/Overweight, combined with the absence of any Sell ratings, suggests strong conviction in the recovery thesis, but the wide $56 target spread and the stock's 31.5-point underperformance versus SPY over the past year indicate that the market has yet to validate the analysts' optimism.
Drowning in data?
Find the real signal!
Bulls vs Bears: CBRE Investment Factors
The bull case rests on a clear cyclical recovery: revenue growth of 18.15% YoY, net income nearly doubling, and a forward PE of 15.45x that looks reasonable if earnings normalize. Analyst consensus is overwhelmingly positive with a $182.92 average target implying 30.2% upside, and the stock has bounced 32.6% from its 52-week low. However, the bear case is equally compelling: CBRE has underperformed the S&P 500 by 31.52 percentage points over the past year, margins remain thin at 3.02% net, and Q1 free cash flow was deeply negative at -$906 million. The most important tension is whether the revenue acceleration reflects a durable cyclical recovery or simply easier comparisons and seasonal working capital dynamics. If the recovery proves genuine and operating leverage continues, the forward PE of 15.45x is a bargain; if it stalls, the trailing PE of 41.44x and PB of 5.40x leave significant downside. On balance, the evidence slightly favors the bulls given the accelerating revenue, doubling net income, and unanimous analyst buy ratings, but the market's skepticism reflected in the 31.5-point underperformance suggests the recovery is not yet proven.
Bullish
- Revenue growth accelerating at 18.2% YoY: Q1 2026 revenue of $10.53 billion rose 18.15% from $8.91 billion in Q1 2025, a sharp acceleration from the prior-year comparison. The sequential progression through 2025 ($8.91B, $9.75B, $10.26B, $11.63B) shows consistent top-line expansion, suggesting a genuine cyclical recovery in commercial real estate transactions rather than just easier comparisons.
- Operating leverage driving earnings surge: Net income nearly doubled from $163 million in Q1 2025 to $318 million in Q1 2026, while EBITDA rose from $518 million to $695 million over the same period. Operating margin improved to 4.85% in Q1 2026 from 1.87% in Q4 2025, indicating that incremental revenue is dropping through to the bottom line as the business scales.
- Analyst consensus bullish with 30% upside: All 12 covering analysts rate CBRE a buy (recommendation mean 1.54), with an average target price of $182.92 implying 30.2% upside from $140.51. The high target of $200.00 suggests 42.3% upside, and recent actions from UBS (upgrade to Buy), Barclays, Evercore ISI, and KBW have all been positive with no downgrades.
- Forward PE of 15.45x is reasonable: While the trailing PE of 41.44x looks expensive, the forward PE of 15.45x based on consensus EPS of $13.45 is far more economically meaningful and reasonable for a market-leading services franchise. The enormous gap implies the market expects earnings to roughly triple as cyclical recovery and operating leverage materialize.
Bearish
- Severe underperformance versus S&P 500: CBRE is down 15.30% over the past year while the S&P 500 gained 16.22%, a massive 31.52 percentage point underperformance. The stock is also down 12.29% year-to-date versus SPY's 12.08% gain, and its 27.37% maximum drawdown underscores how much damage has been done to the prior uptrend.
- Thin and volatile margins: Q1 2026 net margin was just 3.02% and gross margin 17.59%, structurally low for a services business. Gross margin has been volatile, swinging from 19.40% in Q3 2025 to 15.29% in Q4 2025 to 17.59% in Q1 2026, and operating margin of 4.85% leaves little cushion for error if transaction volumes stall.
- Negative free cash flow and working capital drain: Q1 2026 free cash flow was negative $906 million due to a $1.86 billion working capital outflow and $825 million of negative operating cash flow. While this is a seasonal pattern also seen in Q1 2025 (-$610 million), the larger outflow this year raises questions about cash conversion as the business scales.
- Elevated valuation multiples versus history: The trailing PE of 41.44x is near the upper end of its 3-year range (12.06x to 73.99x), and the PB ratio of 5.40x is near the high end of its historical range (2.72x to 5.49x). The PEG ratio of 1.82 indicates the stock is not cheap relative to its growth rate, and EV/EBITDA of 21.71x suggests a premium is being paid for the asset-light earnings stream.
CBRE Technical Analysis
CBRE is in a recovery phase within a longer-term downtrend, with the current price of $140.51 sitting roughly 32.6% above its 52-week low of $121.69 but 19.4% below its 52-week high of $174.27, placing it at approximately 41% of its 52-week range. The 1-year price change of -15.30% confirms that the longer-term trend remains negative, and the stock's position in the lower-middle portion of its range suggests neither a momentum breakout nor a deep-value washout, but rather a market still searching for direction. The 27.37% maximum drawdown over the past year underscores how much damage has been done to the prior uptrend, and until the stock reclaims the $155-160 zone, rallies should be treated as countertrend moves within a broader repair process. Recent momentum is mixed and diverging from the longer-term trend: the 1-month change of -4.67% shows fresh weakness, while the 3-month change of +5.32% and 6-month change of +5.01% indicate that the intermediate trend has been modestly positive. This divergence suggests the stock is in a choppy consolidation rather than a clean trend, with the September pullback from the August high of $155.07 to $137.99 representing a roughly 11% retracement that has since stabilized with a +1.83% bounce to $140.51. Relative strength tells the same story of underperformance: CBRE trails SPY by 3.61 percentage points over 1 month and by a striking 31.52 percentage points over 1 year, though it has outperformed SPY by 2.28 points over 3 months, implying the stock is losing the long game while winning selectively on shorter horizons. Key technical levels are well defined: support rests at the 52-week low of $121.69, with secondary support near the May-June consolidation zone around $124-126, while resistance sits at the 52-week high of $174.27 and intermediate resistance near $155 (the August swing high). A decisive break above $155 would signal that the recovery has legs and could open a path toward the $174 high, whereas a breakdown below $121.69 would confirm the downtrend's resumption and likely trigger momentum-driven selling. With a beta of 1.188, CBRE is roughly 19% more volatile than the broader market, meaning position sizing should account for amplified moves in both directions, and the short ratio of 3.51 days indicates a modest but non-trivial short base that could fuel a squeeze on any upside catalyst.
Beta
1.19
1.19x market volatility
Max Drawdown
-27.4%
Largest decline past year
52-Week Range
$122-$174
Price range past year
Annual Return
-15.3%
Cumulative gain past year
| Period | CBRE Return | S&P 500 |
|---|---|---|
| 1m | -4.7% | -1.6% |
| 3m | +5.3% | +1.3% |
| 6m | +5.0% | +13.9% |
| 1y | -15.3% | +16.3% |
| ytd | -12.3% | +12.1% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CBRE Fundamental Analysis
CBRE's revenue trajectory is clearly re-accelerating, with Q1 2026 revenue of $10.53 billion representing 18.15% year-over-year growth versus $8.91 billion in Q1 2025, a sharp improvement from the prior-year comparison. The multi-quarter trend is constructive: revenue climbed from $8.39 billion in Q2 2024 to $9.75 billion in Q2 2025 to $10.53 billion in Q1 2026, and the sequential progression through 2025 ($8.91B, $9.75B, $10.26B, $11.63B) shows consistent top-line expansion. Segment data indicates the Advisory Services business at $2.02 billion and Project Management at $1.84 billion are the primary growth engines, while the much smaller Real Estate Investments segment at $199 million remains a marginal contributor. The key question for investors is whether this revenue acceleration reflects a genuine cyclical recovery in commercial real estate transactions or simply easier comparisons, and the 18.15% growth rate suggests the former is at least partially true. Profitability is positive but thin, with Q1 2026 net income of $318 million on a 3.02% net margin and gross margin of 17.59%, a level that is structurally low for a services business but typical of a pass-through-heavy real estate services model. Margins have been volatile: gross margin was 19.40% in Q3 2025, 15.29% in Q4 2025, and 17.59% in Q1 2026, while operating margin of 4.85% in Q1 2026 improved from 1.87% in Q4 2025 and 4.69% in Q3 2025. The encouraging sign is that net income has grown from $163 million in Q1 2025 to $318 million in Q1 2026, nearly doubling, and EBITDA rose from $518 million to $695 million over the same period, indicating that operating leverage is beginning to materialize as revenue scales. The balance sheet is moderately leveraged with a debt-to-equity ratio of 1.125 and a current ratio of 1.095, leaving limited liquidity cushion, while ROE of 13.03% and ROA of 2.59% reflect the asset-light but capital-intensive working capital dynamics of the business. Free cash flow is a concern: TTM FCF stands at $897 million, but Q1 2026 free cash flow was negative $906 million due to a $1.86 billion working capital outflow and $825 million of negative operating cash flow, a seasonal pattern also seen in Q1 2025 (-$610 million). The company returned capital aggressively with $530 million of stock repurchases in Q1 2026 and $1.05 billion of debt repayment, funded partly by $545 million of net financing inflows, which suggests CBRE is comfortable with its liquidity but leaves less room for error if the transaction recovery stalls.
Quarterly Revenue
$10.5B
2026-03
Revenue YoY Growth
+18.1%
YoY Comparison
Gross Margin
17.6%
Latest Quarter
Free Cash Flow
$897000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CBRE Overvalued?
Because CBRE is profitable with positive net income of $318 million in Q1 2026, the PE ratio is the appropriate primary metric, and the trailing PE of 41.44x stands in stark contrast to the forward PE of 15.45x. This enormous gap implies the market expects earnings to roughly triple, a projection supported by the analyst consensus EPS estimate of $13.45 for the forward period versus the trailing EPS of $0.024, though the trailing figure appears distorted by quarterly seasonality and one-time items. The forward PE of 15.45x is the more economically meaningful number and suggests that, on normalized earnings, CBRE trades at a reasonable multiple for a market-leading services franchise. On a peer comparison basis, the data provided does not include a direct industry average PE for the Real Estate Services sector, but the broader context is instructive: CBRE's PS ratio of 1.18x and EV/Sales of 1.145x are low on an absolute basis, while its PB ratio of 5.40x and EV/EBITDA of 21.71x suggest the market is paying a premium for the asset-light earnings stream. The PEG ratio of 1.82 indicates the stock is not cheap relative to its growth rate, and the PCF ratio of 30.75x reflects the working-capital-driven volatility in cash generation. Without a sector benchmark in the provided data, the most defensible conclusion is that CBRE trades at a modest premium to book and EBITDA but a discount to sales, consistent with a high-volume, low-margin intermediary rather than a capital-intensive landlord. Historical context is critical here: CBRE's PE ratio has ranged from 12.06x in Q3 2022 to 73.99x in Q4 2022, with recent quarters at 31.36x (Q1 2026), 28.71x (Q4 2025), and 32.29x (Q3 2025), placing the current 41.44x trailing PE near the upper end of its 3-year band. The PB ratio of 5.40x is also near the high end of its historical range, which spanned roughly 2.72x to 5.49x over the past three years, suggesting the market is pricing in optimistic expectations for a cyclical recovery. The PS ratio of 1.18x, by contrast, is well below the 2.87x-4.80x range seen in 2021-2022, indicating that the sales multiple has compressed even as earnings multiples expanded, a classic signature of margin compression that the market expects to reverse.
PE
41.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~74x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.7x
Enterprise Value Multiple
Investment Risk Disclosure
CBRE's financial risks center on its thin margins and working-capital-driven cash flow volatility. Q1 2026 net margin was just 3.02% and gross margin 17.59%, leaving minimal buffer if transaction volumes decline. The company generated negative free cash flow of $906 million in Q1 2026 due to a $1.86 billion working capital outflow, a seasonal pattern but larger than the -$610 million in Q1 2025. With a debt-to-equity ratio of 1.125 and current ratio of 1.095, liquidity is adequate but not abundant, and the company returned $530 million via buybacks and $1.05 billion in debt repayment in Q1 2026, reducing financial flexibility. Additionally, revenue is concentrated in Advisory Services ($2.02 billion) and Project Management ($1.84 billion), making the company highly sensitive to commercial real estate transaction volumes and corporate spending cycles.
Market and competitive risks are significant given CBRE's premium valuation and cyclical exposure. The trailing PE of 41.44x is near the upper end of its 3-year range, and the PB ratio of 5.40x is near historical highs, leaving little room for disappointment. With a beta of 1.188, CBRE is roughly 19% more volatile than the broader market, amplifying downside moves during risk-off periods. The stock has already underperformed SPY by 31.52 percentage points over the past year, and recent news highlights a rotation away from automation-vulnerable sectors toward AI infrastructure and defensive plays, a headwind for real estate services. Competitive pressures from technology-enabled brokerage platforms and in-house corporate real estate teams could erode CBRE's market share and pricing power over time.
The worst-case scenario would involve a stalled commercial real estate recovery, with transaction volumes failing to materialize and margins remaining compressed near 3%. In this scenario, the stock could retest its 52-week low of $121.69, representing a 13.4% decline from the current price of $140.51. If the recovery reverses entirely and the market re-rates the stock toward its historical low-end PE of 12x on depressed earnings, the downside could extend toward the analyst low target of $144.00 (which is actually above the current price, but in a severe bear case, targets would be revised lower). A more realistic worst-case downside is a drop to the $121-125 support zone, a loss of 11-13% from current levels, with a tail risk of a decline to the $100-110 range if a recession hits and transaction volumes collapse, implying a 22-29% loss. The 27.37% maximum drawdown over the past year provides a recent benchmark for how much damage this stock can suffer in a downturn.
FAQ
The most severe risk is a stall in commercial real estate transaction volumes, which would keep margins compressed near 3% and prevent the earnings normalization implied by the forward PE of 15.45x. Second, financial risks include negative free cash flow (-$906 million in Q1 2026) and moderate leverage (debt-to-equity of 1.125), which could strain liquidity if the recovery delays. Third, market risks include the stock's high beta of 1.188 and its 31.52 percentage point underperformance versus SPY over the past year, making it vulnerable to sector rotation away from real estate. Fourth, competitive risks from technology-enabled brokerage platforms could erode CBRE's market share and pricing power. Ranked by severity: cyclical stall (highest), cash flow/liquidity, market rotation, and competition.
Our 12-month forecast has three scenarios: Bull case (30% probability) targets $182.92-$200.00, assuming full cyclical recovery, revenue growth above 20%, and operating margin expansion to 6-7%. Base case (50% probability) targets $155-$175, assuming gradual recovery with revenue growth of 10-15% and margins improving to 5-6%. Bear case (20% probability) targets $121.69-$144.00, assuming a stalled recovery, revenue growth below 10%, and margins remaining near 3%. The base case is most likely, hinging on CBRE meeting consensus EPS of $13.45 and demonstrating positive free cash flow in Q2 and Q3. The key assumption is that commercial real estate transaction volumes continue to recover without a macro shock.
CBRE's valuation is mixed: the trailing PE of 41.44x and PB of 5.40x are near the high end of their 3-year ranges, suggesting the stock is overvalued on historical earnings and book value. However, the forward PE of 15.45x based on consensus EPS of $13.45 is reasonable and implies the market expects earnings to roughly triple as the cycle recovers. The PS ratio of 1.18x and EV/Sales of 1.145x are low on an absolute basis, indicating the market is not paying a premium for revenue. The PEG ratio of 1.82 suggests the stock is not cheap relative to its growth rate. Overall, the market is pricing in a successful recovery; if earnings normalize as expected, the stock is undervalued on a forward basis, but if the recovery stalls, the trailing multiples leave significant downside.
From a risk/reward perspective, CBRE offers a favorable setup with 30.2% upside to the analyst average target of $182.92, against a downside to the 52-week low of $121.69 (13.4% below current). The forward PE of 15.45x is reasonable for a market leader, and the unanimous buy consensus (12 analysts, mean 1.54) suggests strong conviction in the recovery. However, the stock has underperformed SPY by 31.52 percentage points over the past year, and thin margins (3.02% net) mean the thesis hinges on continued revenue acceleration. It is a good buy for investors with a 12-18 month horizon who believe in the commercial real estate recovery and can tolerate volatility (beta 1.188). For short-term traders, the choppy consolidation and lack of a clear trend make it less attractive.
CBRE is better suited for medium-to-long-term investment (minimum 12-18 months) rather than short-term trading. The stock is in a recovery phase with a beta of 1.188, meaning it is 19% more volatile than the market, and its 27.37% maximum drawdown over the past year shows it can experience sharp declines. The lack of a dividend (payout ratio 0) means returns depend entirely on capital appreciation, and the cyclical nature of the business requires time for the recovery to play out. Earnings visibility is moderate, with analyst EPS estimates ranging from $13.05 to $14.30, and the wide target price spread ($144-$200) indicates uncertainty. Short-term traders may find opportunities around earnings or technical breakouts, but the choppy consolidation and negative 1-month momentum (-4.67%) make timing difficult. A minimum holding period of 12-18 months allows the cyclical recovery and operating leverage to materialize.
